Shots:
- BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics, incl. its P-I/II asset ALE1, an oral small molecule for the treatment of hypophosphatasia
- As per the deal, BioMarin will acquire Alesta, with Alesta shareholders receiving $275M upfront & ~$215M in development & regulatory milestone payments
- Before closing, Alesta will spin out all non-ALE1 assets into a new entity, with former employees transferring to the spinout, meaning no Alesta employees will join BioMarin
Ref: PRnewswire | Image: Alesta Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
